secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hims & Hers Health, Inc. (HIMS)
CIK:        0001773751
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001773751-26-000019
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hims & Hers FY2025 revenue up 59% to $2.35B, adj. EBITDA $318M; guides FY2026 rev $2.7-2.9B
--------------------------------------------------------------------------------

- Revenue $2.35B (+59% YoY); net income $128M; adj. EBITDA $318M vs $177M prior year.
- Q4 revenue $618M (+28% YoY); net income $20.6M; adj. EBITDA $66.3M.
- Subscribers at 2.5M (+13% YoY); monthly revenue per avg subscriber $83 (+28% YoY).
- FY2026 guidance: revenue $2.7-2.9B, adj. EBITDA $300-375M; excludes potential Eucalyptus acquisition.
- Non-GLP-1 revenue majority; compounded semaglutide access assumed in guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/0001773751-26-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/hims-20260223.htm
  HTML page:      https://secwatch.observer/filing/0001773751-26-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer